

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

Inventor(s): Mayweg et al.

Group:

Serial No. Not yet known, filed Herein

Examiner:

For: NOVEL CB 1 RECEPTOR INVERSE AGONISTS

INFORMATION DISCLOSURE STATEMENT

Nutley, New Jersey 07110
December 22, 2003

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicants respectfully direct the Examiner's attention to the documents listed on enclosed Form PTO-1449.

Documents B1-B13 and C1-C7 listed on Form PTO-1449 are enclosed.


Documents A1-A3 are not enclosed since they are U.S. Patents.

Consideration of all the documents cited on Form PTO-1449 is requested.

Serial No. Not yet known
Filed: Herein

Since the Information Disclosure Statement is submitted before the mailing of the first Office Action on the merits or within three months of the filing date for the above application, no fee is due.

Respectfully submitted,



Agent for Applicant(s)
Lyman H. Smith
(Reg. No. 44,342)
340 Kingsland Street
Nutley, New Jersey 07110
Telephone: (973) 235-3916
Telefax: (973) 235-2363

137415

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				Complete if Known	
				Application Number	Not yet known
				Filing Date	Herein
				First Name Inventor	Alexander Mayweg
				Group Art Unit	
				Examiner Name	
Sheet	1	of	1	Attorney Docket Number	21554

U.S. PATENT DOCUMENTS					
Examiner Initials ¹	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited document MM-DD-YYYY
		Number	Kind Code ² (if known)		
	A1	5624941		Sanofi	04-29-1997
	A2	3940418		G.D. Searle & Co.	02-24-1976
	A3	5596106		Eli Lilly and Company	01-21-1997

FOREIGN PATENT DOCUMENTS							
Examiner Initials'	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)			
	B1	WO0015609			Aventis Pharma S.A.	03-23-2000	√
	B2	WO0164634			Aventis Pharma S.A.	09-07-2001	√
	B3	WO0228346			Aventis Pharma S.A.	04-11-2002	√
	B4	WO0164632			Aventis Pharma S.A.	09-07-2001	√
	B5	WO0164633			Aventis Pharma S.A.	09-07-2001	√
	B6	WO0170700			Solvay Pharmaceuticals B.V.	09-27-2001	
	B7	WO0132663			Sanofi-Synthelabo	05-10-2001	√
	B8	WO0046209			Sanofi-Synthelabo	08-01-2000	√
	B9	WO9719063			Sanofi	05-29-1997	
	B10	EP658546			Sanofi-Synthelabo	06-21-1995	√
	B11	EP656354			Sanofi	06-07-1995	√
	B12	EP576357			Sanofi	12-29-1993	√
	B13	WO9602248			Eli Lilly and Company	02-01-1996	√
Examiner Signature							

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation or abstract is attached.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				Complete if Known	
				Application Number	Not yet known
				Filing Date	Herein
				First Name Inventor	Alexander Mayweg
				Group Art Unit	
				Examiner Name	
Sheet	2	Of	2	Attorney Docket Number	21554

NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	C1	PACHECO, M., ET AL., Aminoalkylindoles: Actions on Specific G-Protein-Linked Receptors, Journal of Pharmacology and Experimental Therapeutics, 1991, pp. 170-183, v. 257(1)	
	C2	CASIANO, F.M., ET AL., Putative Aminoalkylindoles (AAI) Antagonists, Problems of Drug Dependence 1990: Proceedings of the 52 nd Annual Scientific Meeting The Committee on Problems of Drug Dependence, 1991, pp. 295-296, v. 105	
	C3	HOSOHATA, K., ET AL., AM630 is a Competitive Cannabinoid Receptor Antagonist in the Guinea Pig Brain, Life Sciences, 1997, pp. 115-118, v. 61(9)	
	C4	PERTWEE, R., ET AL., AM630, A Competitive Cannabinoid Receptor Antagonist, Life Sciences, 1995, pp. 1949-1955, v. 56(23/24)	
	C5	FELDER, C.C., ET AL., LY320135, a Novel Cannabinoid CB1 Receptor Antagonist, Unmasks Coupling of the CB1 Receptor to Stimulation of cAMP Accumulation, Journal of Pharmacology and Experimental Therapeutics, 1998, pp. 291-297, v. 284(1)	
	C6	KANYONYO, M. ET AL., 3-Alkyl-(5,5'-Diphenyl) Imidazolidinediones As New Cannabinoid Ligands, Bioorganic & Medicinal Chemistry Letters, 1999, pp.2233-2236, v. 9	
	C7	OOMS, F., ET AL., Exploration of the Pharmacophore of 3-Alkyl-5-Arylimidazolidinediones as New CB ₁ Cannabinoid Receptor Ligands and Potential Antagonists: Synthesis, Lipophilicity, Affinity, and Molecular Modeling, J. Med. Chem., 2002, pp.1748-1756, v. 45(9)	
Examiner Signature	DATE CONSIDERED		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation or abstract is attached.